277 related articles for article (PubMed ID: 25486600)
21. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
Loriot Y; Fizazi K
Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
[No Abstract] [Full Text] [Related]
22. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
23. The third line of treatment for metastatic prostate cancer patients: Option or strategy?
Roviello G; Petrioli R; Laera L; Francini E
Crit Rev Oncol Hematol; 2015 Sep; 95(3):265-71. PubMed ID: 26052050
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Tombal B
Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
[No Abstract] [Full Text] [Related]
26. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
[TBL] [Abstract][Full Text] [Related]
27. [How to manage patients with CRPC?].
Beuzeboc P; Massard C
Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
[TBL] [Abstract][Full Text] [Related]
28. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
29. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
30. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
[TBL] [Abstract][Full Text] [Related]
31. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D;
Prostate; 2015 Jun; 75(8):836-44. PubMed ID: 25683285
[TBL] [Abstract][Full Text] [Related]
32. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
33. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
[TBL] [Abstract][Full Text] [Related]
34. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
35. [Bone and calcium metabolism associated with malignancy. Bone metastasis of prostate cancer:overview of clinical features and treatments.].
Suzuki K; Miyazawa Y
Clin Calcium; 2018; 28(11):1441-1449. PubMed ID: 30373999
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
[TBL] [Abstract][Full Text] [Related]
37. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
39. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
40. Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
Ahmed ME; Andrews JR; Alamiri J; Higa J; Haloi R; Alom M; Motterle G; Joshi V; Shah PH; Jeffrey Karnes R; Kwon E
Prostate; 2020 Oct; 80(14):1216-1222. PubMed ID: 32735712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]